Prognosis
Pfizer, BioNTech Start Late-Stage Study of Lead Covid Shot
- Companies set October as goal for seeking regulatory review
- Moderna announced its final-state vaccine trial earlier Monday
This article is for subscribers only.
Sign up here for our daily coronavirus newsletter on what you need to know, and subscribe to our Covid-19 podcast for the latest news and analysis.
Pfizer Inc. and BioNTech SE said they’ve begun a later-stage trial for their top coronavirus vaccine candidate and set a goal of submitting it for regulatory review as soon as October -- one of the most ambitious timelines to date.